FOXO4-DRI (10mg) is a synthetic senolytic peptide designed to selectively trigger apoptosis (programmed cell death) in senescent cells (aged cells that have stopped dividing). By blocking the interaction between the FOXO4 protein and the tumor suppressor p53, it allows these aged cells to be cleared out.
Research into FOXO4-DRI is strictly limited to in-vitro (lab) and animal (mouse) studies. It is not FDA-approved, nor is it intended for human or animal consumption.
Key Specifications & Context
-
- Mechanism: It interferes with the FOXO4-p53 pathway, prompting p53 nuclear exclusion which initiates the apoptotic cascade.
- Research Focus: Scientific models explore its potential to reverse age-related physical decline, improve organ function, and clear senescent cells in tissues.
- Reconstitution: Typically supplied as a 10mg lyophilized powder requiring reconstitution (usually with 1mL of sterile water) for laboratory use.
Availability and Sourcing
- Research Suppliers: Available through chemical and biochemical vendors for scientific investigation.
- Pricing: Vials of 10mg typically range between $119 to $150 depending on the supplier.




Reviews
There are no reviews yet.